Magdalena Tyrpien is a leader in US HealthTech. As Co-Founder & CEO of Nionyx Bio, she focuses on engineering gene therapy with precision, safety, and true targeting, starting with the kidney. Previously, as Chief Business Officer at Forge Biologics, she helped accelerate access to potentially life-saving AAV gene therapies. Magdalena is a member of the American Society of Cell and Gene Therapy and the Executive Women’s Council of the Alliance of Regenerative Medicine.
666 3rd Ave, 6th Floor, New York, NY 10017